BeiGene (NASDAQ: BGNE; HKG: 6160; SHA: 688235), a biopharmaceutical company, has announced that its programmed-death (PD)-1 monoclonal antibody (mAb), tislelizumab, has received approval from the National Medical Products Administration (NMPA) in China. The drug is now approved to be used in combination with chemotherapy for the treatment of patients with first-line extensive stage small cell lung cancer (ES-SCLC).
Since its initial marketing approval in China in December 2019, tislelizumab has garnered 14 indication approvals. The drug also achieved its first approval in the U.S. in September last year, marking a significant milestone for BeiGene as it continues to expand the global reach of its product portfolio.- Fineline.com
